

## Caldera Health founder steps down as Director of Science

**Auckland, 2 February 2015** – The Chairman of Caldera Health, Dr Alastair MacCormick today announced that Dr Jim Watson will be stepped asiding from his role as Director of Science, citing health issues, and has resigned as a Director of the company which he founded with Dr Richard Forster in 2009. Both changes will be effective 28 February 2015.

“Jim has led this company since its formation,” said Dr MacCormick. “He will continue to maintain a strong interest in its progress and to be associated with its work. However he has personal matters to attend to which preclude him from continuing his current level of day-to-day involvement.”

In December 2014, at its Annual Meeting, the company indicated to shareholders that it had begun a search for a new full-time CEO to lead the business though its next phase, including driving the commercial licensing of the novel clinical tools that Caldera develops for diagnosing prostate cancer. Graham Watt will continue as Managing Director until the CEO is appointed, after which he will continue as a director and consultant to the Company, with special responsibility for commercialisation of Caldera’s technology.

“Clinical Study 2, which commenced in July 2014, is now entering its final stages under the direction of Dr Kristen Chalmet, our Chief Scientist,” said Dr MacCormick. “Jim has undertaken to work with Kristen and her team to see that study through to a successful conclusion. Once that milestone is achieved the company will turn its attention to concluding strategic partnerships and developing diagnostic tests suitable for clinical use.”

ENDS

### About Caldera Health

Caldera Health develops diagnostic tools to fundamentally change the way clinicians detect and monitor prostate cancer. Caldera uses next-generation gene sequencing technology to measure the levels of selected RNA biomarkers in urine, blood and tissue to identify genetic changes occurring in different forms of cancer. The company’s business goal is to replace the PSA test, the current standard diagnostic tool, with a new, more reliable global standard.

For further information please contact

Dr Alastair MacCormick, +64 21 640 010, [a.maccormick@xtra.co.nz](mailto:a.maccormick@xtra.co.nz)

Allan Botica, +64 21 400 500, [allanb@botica.co.nz](mailto:allanb@botica.co.nz)